Please wait...

Novoseven rt

Generic Name: coagulation factor VIIa (injection) (koe AG yoo LAY shun FAK tor)
Brand Name: NovoSeven RT with MixPro
Physician reviewed NovoSeven RT with MixPro (injection) (injection) patient information - includes NovoSeven RT with MixPro (injection) description, dosage and directions.
  • Prescription Settings

Prices and coupons of Novoseven rt

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
NovoSeven RT with MixPro is a man-made protein similar to a natural protein in the body that helps the blood to clot. NovoSeven RT with MixPro is used to treat or prevent bleeding in people with hemophilia A or hemophilia B, or factor VII deficiency. NovoSeven RT with MixPro may also be used for purposes not listed in this medication guide. If possible before you receive NovoSeven RT with MixPro, tell your doctor about all your medical conditions and allergies. Also make sure your doctor knows if you are pregnant or breast-feeding. Learn more

Novoseven rt Side Effects

NovoSeven RT Side Effects

Note: This document contains side effect information about coagulation factor viia. Some of the dosage forms listed on this page may not apply to the brand name NovoSeven RT.

For the Consumer

Applies to coagulation factor viia: intravenous powder for solution


Intravenous route (Powder for Solution)

Serious arterial and venous thrombotic events are associated with the use of coagulation factor VIIa. Patients should be advised of the risks and know the signs and symptoms of thrombotic and thromboembolic events. Monitor for signs/symptoms of thrombosis and of activation of the coagulation cascade.

Along with its needed effects, coagulation factor viia (the active ingredient contained in NovoSeven RT) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking coagulation factor viia:

More common

  • Bleeding problems
  • fever
  • high blood pressure
  • joint or muscle pain or stiffness

Less common or rare

  • Bloating or swelling of the face, hands, lower legs, or feet
  • bluish color of the hands or feet
  • blurred vision
  • changes in facial color
  • chest pain
  • chills
  • cold sweats
  • confusion
  • continuing thirst
  • cough
  • dizziness
  • excessive sweating
  • faintness
  • fast heartbeat
  • hives, itching, or skin rash
  • large flat blue or purplish patches on the skin
  • lightheadedness when getting up suddenly from a lying or sitting position
  • persistent bleeding or oozing from puncture sites or mucous membranes (bowel, mouth, nose, or urinary bladder)
  • puffiness or swelling of the eyelids or around the eyes
  • shakiness
  • slow or irregular heartbeat (less than 50 beats per minute)
  • slurred speech
  • sneezing
  • sore throat
  • sudden decrease in the amount of urine
  • swelling of the face, fingers, feet, or lower legs
  • troubled breathing, tightness in the chest
  • unusual tiredness or weakness
  • unusual weight gain

Some side effects of coagulation factor viia may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common or rare

  • Burning or stinging at the injection site
  • drowsiness
  • feeling of warmth
  • headache
  • nausea or vomiting
  • pinpoint red or purple spots on the skin
  • redness of the face, neck, arms and occasionally, upper chest

For Healthcare Professionals

Applies to coagulation factor viia: intravenous powder for injection


The most common adverse reactions were thrombotic events.


Common (1% to 10%): Hypertension, thromboembolic events

Uncommon (0.1% to 1%): Shock

Rare (less than 0.1%): Angina pectoris

Postmarketing reports: Intracardiac thrombus, flushing

Specific arterial thromboembolic events (cerebral artery occlusion, cerebrovascular accident), specific venous thromboembolic events (pulmonary embolism, deep vein thrombosis), and angina pectoris were reported with a frequency of common (1% to 10%) in clinical trials of 61 patients with acquired hemophilia.


Common (1% to 10%): Plasma fibrinogen decreased, acute post-operative hemarthrosis

Rare (less than 0.1%): Disseminated intravascular coagulation, D dimer increased, antithrombin decreased, coagulopathy, fibrin degradation products increased, alkaline phosphatase increased, lactate dehydrogenase increased, prothrombin increased


Antibody formation against this drug has only been reported in patients with factor VII deficiency.

Common (1% to 10%): Antibody formation against this drug

Rare (less than 0.1%): Hypersensitivity

Postmarketing reports: Anaphylactic reaction

Nervous system

Common (1% to 10%): Intracranial hypertension, headache

Uncommon (0.1% to 1%): Cerebrovascular accident

Frequency not reported: Cerebrovascular disorder


Common (1% to 10%): Localized phlebitis

Rare (less than 0.1%): Injection site reaction


Common (1% to 10%): Fever

Frequency not reported: Pain


Uncommon (0.1% to 1%): Rash, pruritus, urticaria

Postmarketing reports: Angioedema


Uncommon (0.1% to 1%): Nausea


Uncommon (0.1% to 1%): Dyspnea


Rare (less than 0.1%): Alanine aminotransferase increased

Frequency not reported: Abnormal hepatic function

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Novoseven Rt